Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors
NCT02929615 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2016-10-12
Summary
The purpose of the study is to research the standard and individualized treatment model for relapse and refractory lymphatic system malignant tumors.
Conditions
Interventions
- OTHER
-
Hematopoietic stem cell transplantation
Sponsors & Collaborators
-
Peking University
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-06-30
- Primary Completion
- 2017-12-31
- Completion
- 2018-03-31
Countries
- China
Study Locations
More Related Trials
-
Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma
NCT05590221 ·Status: RECRUITING ·Phase: PHASE2
-
Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse
NCT01562990 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
NCT01359592 ·Status: COMPLETED ·Phase: PHASE2
-
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
NCT06651853 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
NCT05182957 ·Status: RECRUITING ·Phase: PHASE2
-
Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05221645 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
NCT02981745 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation
NCT02905942 ·Status: UNKNOWN ·Phase: PHASE4
-
Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection
NCT06541327 ·Status: RECRUITING
-
Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL
NCT05552937 ·Status: RECRUITING ·Phase: PHASE2
-
Translational Study of Molecular Classification of Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05318391 ·Status: COMPLETED
-
Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma
NCT05179213 ·Status: UNKNOWN ·Phase: PHASE2
-
Glofitamab in Chinese Patients With R/R DLBCL
NCT06481826 ·Status: RECRUITING
-
Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study
NCT04296786 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
NCT05444322 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Frontline of ASCT in High-risk DLBCL
NCT05831865 ·Status: RECRUITING
-
A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)
NCT04129710 ·Status: RECRUITING ·Phase: PHASE2
-
Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
NCT05186558 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Safety and Efficacy of BKM120 in Relapsed and Refractory NHL
NCT01693614 ·Status: COMPLETED ·Phase: PHASE2
-
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
NCT03493451 ·Status: COMPLETED ·Phase: PHASE2
-
Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.
NCT05821192 ·Status: UNKNOWN ·Phase: NA
-
Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma
NCT00366275 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT01741792 ·Status: COMPLETED ·Phase: PHASE2
-
Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma
NCT04425824 ·Status: UNKNOWN ·Phase: PHASE2
-
Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma
NCT00039195 ·Status: COMPLETED ·Phase: PHASE2